Key Statistics for KDEV
|Current P/E Ratio (ttm)
Relative P/E vs.
|Earnings Per Share (SEK) (ttm)
|Est. EPS (SEK) (12/2013)
|Est. PEG Ratio
|Market Cap (M SEK)
|Shares Outstanding (M)
|30 Day Average Volume
|Dividend Indicated Gross Yield
|5 Year Dividend Growth
|Next Earnings Announcement
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for KDEV
- Net Income (M/SEK)
Karolinska Development AB manages a portfolio of life science companies in Europe. The Company's portfolio companies are focused on pharmaceutical development across a broad range of therapeutic areas. Karolinsk's portfolio also encompasses companies developing theranostics as well as medical and formulation technologies.
More Company Profile & Key Executives for KDEV
|Hans WigzellChairman||Torbjorn BjerkeChief Executive Officer|
|Robin WrightCFO/Head:Business Development||Terje KallandDeputy CEO/Chief Scientific Ofcr|
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.